Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.

Daniel MorgenszternBenjamin BesseLaurent GreillierRafael Santana-DavilaNeal ReadyChristine L HannBonnie S GlissonAnna F FaragoAfshin DowlatiCharles M RudinSylvestre Le MoulecSatwant LallySreeni YalamanchiliJürgen WolfRamaswamy GovindanDavid P Carbone

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)

Rova-T is the first targeted agent in SCLC to use DLL3, a novel biomarker. However, results demonstrate modest clinical activity in 3L+ SCLC, with associated toxicities.

Keyphrases

phase ii
small cell lung cancer
clinical trial
open label
acute lymphoblastic leukemia
acute myeloid leukemia
cancer therapy
randomized controlled trial
study protocol
drug delivery